GlassScriptPhysician profile
Charles M Butler
NPI 1881725364
$15,142.19
in general payments reported to CMS, 2019-2025
80 companies · $3,439 in 2025
The $3,439 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,876 · 2020: $594 · 2021: $11.92 · 2022: $1,886 · 2023: $2,900 · 2024: $3,434 · 2025: $3,439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,699 · Education: $74.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,699.04 |
| Education | $74.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,200.69 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $900.12 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $866.68 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $807.82 | 2019-2025 | Tagrisso, Calquence, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $700.99 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Janssen Biotech, INC. | $660.73 | 2019-2025 | Tecvayli, Erleada, Darzalex |
| Takeda Pharmaceuticals U.S.A., INC. | $609.07 | 2019-2025 | Alunbrig, Fruzaqla, Ninlaro |
| Genentech USA, INC. | $569.87 | 2019-2025 | Venclexta, Polivy, Tecentriq |
| Celgene Corporation | $523.12 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Genzyme Corporation | $403.52 | 2019-2025 | |
| Daiichi Sankyo INC. | $400.48 | 2019-2025 | Injectafer, Enhertu, Datroway |
| Lilly USA, LLC | $396.86 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Astellas Pharma US INC | $363.56 | 2019-2025 | Xtandi, Padcev, Xospata |
| Eisai INC. | $305.15 | 2019-2024 | |
| Incyte Corporation | $301.88 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
Show all 80 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $297.70 | 2022-2024 | Rybrevant |
| Rigel Pharmaceuticals, INC. | $272.34 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Amgen INC. | $251.83 | 2019-2020 | |
| Abbvie INC. | $248.02 | 2019-2025 | Venclexta |
| Emd Serono, INC. | $230.69 | 2022-2025 | Bavencio, Tepmetko |
| Bayer Healthcare Pharmaceuticals INC. | $199.41 | 2019-2025 | |
| Aveo Pharmaceuticals, INC. | $199.22 | 2022-2025 | Fotivda |
| Ipsen Biopharmaceuticals, INC | $189.92 | 2019-2024 | Somatuline Depot, Onivyde |
| Regeneron Healthcare Solutions, INC. | $188.81 | 2019-2025 | Libtayo |
| Glaxosmithkline, LLC. | $187.53 | 2022-2025 | Ojjaara, Jemperli, Zejula |
| Eagle Pharmaceuticals, INC. | $187.23 | 2022-2024 | |
| Array Biopharma INC | $185.72 | 2023-2025 | Mektovi, Braftovi, Lorbrena |
| Puma Biotechnology, INC. | $184.26 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $182.18 | 2020-2025 | Zepzelca |
| Gilead Sciences, INC. | $181.58 | 2019-2025 | Trodelvy |
| Seagen INC. | $175.52 | 2019-2023 | Adcetris, Tukysa, Padcev |
| Adc Therapeutics America, INC. | $167.69 | 2022-2025 | |
| Octapharma USA, INC. | $151.98 | 2022 | |
| Taiho Oncology, INC. | $147.56 | 2019-2025 | |
| Exelixis INC. | $132.97 | 2022-2025 | Cabometyx |
| Karyopharm Therapeutics INC. | $122.84 | 2022-2025 | Xpovio |
| Alexion Pharmaceuticals, INC. | $120.75 | 2022-2025 | Ultomiris |
| Foundation Medicine, INC. | $114.67 | 2020 | |
| Servier Pharmaceuticals LLC | $111.35 | 2022-2025 | |
| Spectrum Pharmaceuticals INC. | $101.91 | 2023-2025 | Rolvedon |
| Immunocore Limited | $94.58 | 2024-2025 | Kimmtrak |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.98 | 2019-2025 | Gilotrif |
| Deciphera Pharmaceuticals INC. | $86.90 | 2023-2025 | Qinlock, Romvimza |
| Genmab U.S., INC. | $85.43 | 2022-2024 | Tivdak, Epkinly |
| Sumitomo Pharma America, INC. | $79.83 | 2023-2025 | Orgovyx |
| Sobi, INC | $71.05 | 2023-2025 | |
| Beigene USA, INC. | $68.39 | 2022-2024 | Brukinsa |
| Kyowa Kirin, INC. | $67.77 | 2019-2025 | Poteligeo |
| G1 Therapeutics, INC. | $62.99 | 2022 | |
| Beone Medicines USA, INC. | $60.07 | 2025 | Brukinsa, Tevimbra |
| Mirati Therapeutics, INC. | $56.45 | 2023-2024 | Krazati |
| Blueprint Medicines Corporation | $48.20 | 2022-2025 | Ayvakit |
| Macrogenics, INC. | $47.42 | 2022-2023 | |
| Pharmaessentia USA Corporation | $46.61 | 2024-2025 | Besremi |
| Apellis Pharmaceuticals, INC. | $45.27 | 2025 | Empaveli |
| Janssen Pharmaceuticals, INC | $44.24 | 2020-2024 | Xarelto |
| Coherus Oncology, INC. | $39.85 | 2024-2025 | Loqtorzi |
| Dova Pharmaceuticals | $35.36 | 2019-2020 | |
| Aurobindo Pharma USA, INC. | $33.50 | 2019 | |
| Tersera Therapeutics LLC | $28.78 | 2019 | |
| Secura Bio, INC. | $27.30 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $27.12 | 2019-2022 | |
| Genentech, INC. | $25.79 | 2024 | Columvi, Lunsumio |
| Stemline Therapeutics INC. | $25.74 | 2025 | Orserdu |
| Geron Corporation | $23.62 | 2025 | Rytelo |
| Acrotech Biopharma INC. | $23.40 | 2024 | Beleodaq |
| Agios Pharmaceuticals, INC. | $23.26 | 2019-2020 | |
| Novocure INC. | $22.75 | 2025 | Optune Lua (Novottf-200t) |
| Heron Therapeutics, INC. | $21.69 | 2019 | |
| Cti Biopharma Corp. | $19.98 | 2023 | Vonjo |
| Springworks Therapeutics, INC. | $19.91 | 2025 | Ogsiveo |
| Verastem, INC. | $19.76 | 2025 | Avmapki Fakzynja Co-Pack |
| Kite Pharma, INC. | $18.46 | 2025 | Yescarta |
| Epizyme, INC. | $17.28 | 2022 | |
| Myovant Sciences INC. | $17.19 | 2022 | |
| Morphosys, US INC. | $16.53 | 2022 | |
| Legend Biotech USA INC. | $15.99 | 2025 | Carvykti |
| Pharmacosmos Therapeutics INC. | $14.79 | 2023 | Monoferric |
| Mylan Institutional INC. | $12.57 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $11.17 | 2019 |
Drugs and devices associated with these payments
Keytruda $580Kisqali $337Reblozyl $323Tukysa $281Jaypirca $239Verzenio $239Xtandi $228Rezlidhia $217Tavalisse $217Ibrance $211Mektovi $199Scemblix $198Enhertu $195Braftovi $185Fotivda $182Lynparza $182Pemfexy $174Tecvayli $168Adcetris $163Sarclisa $163Piqray $162Venclexta $162Erleada $158Padcev $158Lenvima $153Orgovyx $153Elrexfio $146Libtayo $135Tagrisso $133Inlyta $132Injectafer $131Darzalex $130Zepzelca $123Altuviiio $121Cabometyx $121Alunbrig $115Rybrevant $114Calquence $112Lunsumio $110Opdivo $105Polivy $104Ultomiris $103Lorbrena $103Rolvedon $102Tecentriq $96.89Kimmtrak $94.58Krazati $93.84Brukinsa $93.69Bosulif $91.54Gavreto $90.82Fruzaqla $90.44Talzenna $88.86Qinlock $86.90Onivyde $85.71Somatuline Depot $85.71Jakafi $85.44Ojjaara $85.39Bavencio $84.33Ninlaro $84.23Xpovio $83.53Welireg $82.31Monjuvi $79.10Elahere $75.60Columvi $72.98Xofigo $71.54Nubeqa $71.54Balversa $71.44Inqovi $65.50Lonsurf $65.50Ayvakit $64.89Talvey $61.71Iclusig $59.22Pemazyre $56.44Opdualag $54.58Poteligeo $54.23Paxlovid $52.22Trodelvy $52.07Akeega $52.07Zejula $51.13Jemperli $51.13Pomalyst $50.71Doptelet $50.33Voranigo $48.98Xospata $47.46Besremi $46.61Zynlonta $46.56Fabhalta $46.20Besponsa $46.19Itovebi $45.58Empaveli $45.27Tivdak $41.17Vonjo $40.70Comirnaty $40.52Tibsovo $40.04Perjeta $38.38Xalkori $37.64Tepmetko $36.87Epkinly $34.48Exkivity $34.29Nerlynx $33.59
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Butler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.